Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients

Abstract

In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).

Keywords

Affiliated Institutions

• Mayo Clinic US
• Scripps Health US
• Yale New Haven Hospital US
• Johns Hopkins Hospital US
• Saint Francis Hospital US
• Medtronic (Ireland) IE
• Winchester Medical Center US
• Paradigm Pharmaceuticals (United States) US
• Hadassah Medical Center IL
• McGill University Health Centre CA
• Aurora St. Luke's Medical Center US
• Clinique Pasteur FR
• OhioHealth US
• Abbott Northwestern Hospital US
• Morton Plant Hospital US
• Riverside Methodist Hospital US
• The Alfred Hospital AU
• University of Pittsburgh Medical Center US
• Corewell Health Blodgett Hospital US
• Scripps Clinic US
• University of Pittsburgh US
• Mount Sinai Health System US
• University of Michigan US
• UPMC Central Pa US
• The University of Kansas Health System US
• Houston Methodist US

Related Publications